France's medicines agency (ANSM) announced on Wednesday that the drug Tavneos (avacopan) is being withdrawn from the French market due to safety concerns. The decision follows a review by European health authorities, which flagged serious adverse effects associated with the medication.
Tavneos, developed by CSL Vifor, was approved for the treatment of certain rare autoimmune diseases, including granulomatosis with polyangiitis and microscopic polyangiitis. However, post-marketing surveillance revealed an increased risk of serious infections and other complications, prompting the European Medicines Agency (EMA) to recommend withdrawal.
The ANSM stated that the withdrawal is effective immediately, and patients currently taking Tavneos will be transitioned to alternative treatments under medical supervision. The agency emphasized that the decision was made to protect patient safety, as the risks now outweigh the benefits.
This action aligns with similar measures taken in other European countries, as the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the drug's risks could not be adequately managed. The manufacturer has agreed to the withdrawal, and further details are expected in the coming days.
